Furthermore, data from the first patients to receive 177Lu-rhPSMA-10.1 under a compassionate use program in Germany show that, within the same patient, 177Lu-rhPSMA-10.1 can deliver up to 8-fold greater radiation doses to the tumour than 177Lu-PSMA-I&T, with 177Lu-rhPSMA-10.1 shown to have a more favourable tumour-to-kidney therapeutic index [22, 23]. The gene discussed is FOLH1; the disease is neoplasm.